COVID-19 in Wisconsin: 18 more deaths, 1,826 cases reported on Sunday Photo: NIAID-RML via AP. FILE - This undated electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2. Also known as 2019-nCoV, the virus causes COVID-19. The sample was isolated from a patient in the U.S. On Tuesday, April 21, 2020, U.S. health regulators OK d the first coronavirus test that allows people to collect their own sample at home, a new approach that could help expand testing options in most states. The sample will still have to be shipped for processing back to LabCorp, which operates diagnostic labs throughout the U.S.
US panel recommends emergency approval of Moderna Covid vaccine
published : 18 Dec 2020 at 08:45
5 Moderna teamed up with scientists from the US National Institutes of Health and began work in January just days after Chinese authorities shared the SARS-CoV-2 virus genome
WASHINGTON - A US panel of experts on Thursday voted to recommend emergency approval of Moderna s Covid-19 vaccine, paving the way for six million doses to start shipping as soon as this weekend.
The Food and Drug Administration is now expected to imminently grant an emergency use authorization (EUA), which would make Moderna s vaccine the second to be approved in a Western country.
Photos show the first batches of Moderna s coronavirus vaccine being packaged and shipped across the US
By insider@insider.com (Connor Perrett,Inyoung Choi) of Business Insider |
Photos show the first batches of Moderna s coronavirus vaccine being packaged and shipped across the US
The Food and Drug Administration on Friday granted an emergency use authorization for the COVID-19 vaccine developed by the biotech firm Moderna and the US National Institutes of Health.
The two-shot Moderna/NIH vaccine was approximately 94.5% effective at preventing COVID-19 in a large clinical trial.
The FDA last week issued the same authorization for the vaccine created by Pfizer and BioNTech, which had a similar rate of success during trials but is harder to store and transport than the Moderna vaccine.
A second coronavirus vaccine has now joined the fight against COVID-19 in the United States.
On December 18, the U.S. Food and Drug Administration authorized Moderna’s vaccine for emergency use in people 18 years or older. The decision follows a thumbs-up vote from a panel of experts that convened on December 17 to discuss vaccine data that the biotechnology company had collected from its ongoing clinical trial.
The vaccine joins a similar one from pharmaceutical company Pfizer and its German partner BioNTech, which was authorized December 11 and has begun to be administered to people in high-risk groups in the United States, including health care workers and people living in nursing homes (
US regulators have authorized a second coronavirus vaccine for emergency use.
This two-dose vaccine, developed by the biotech firm Moderna and the US National Institutes of Health, was about 94% effective at preventing COVID-19 in a large clinical trial.
Moderna s vaccine is easier to store and transport than Pfizer s COVID-19 shot, which got US clearance a week ago.
Moderna plans to deliver 20 million doses in the US by year s end.
The authorization is the latest achievement in a remarkable story of science and business for Moderna, a company that has surged in 2020 based off its COVID-19 success.
The US Food and Drug Administration authorized Moderna s coronavirus shot for emergency use, making the two-dose vaccine the second to be cleared by US regulators.